Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Asset Growth Under PressureDecelerating
Percentile Rank62
3Y CAGR+96.0%
5Y CAGR-4.8%
Year-over-Year Change
Year-over-year total asset growth rate
3Y CAGR
+96.0%/yr
Quarterly compound
5Y CAGR
-4.8%/yr
Recent acceleration
Percentile
P62
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.36% |
| Q3 2025 | 6.26% |
| Q2 2025 | 8.36% |
| Q1 2025 | -0.62% |
| Q4 2024 | 0.83% |
| Q3 2024 | 4.87% |
| Q2 2024 | 4.84% |
| Q1 2024 | -0.14% |
| Q4 2023 | -0.24% |
| Q3 2023 | 12.83% |
| Q2 2023 | 0.31% |
| Q1 2023 | -4.35% |
| Q4 2022 | 0.31% |
| Q3 2022 | 6.15% |
| Q2 2022 | -3.00% |
| Q1 2022 | -5.76% |
| Q4 2021 | 4.92% |
| Q3 2021 | -1.06% |
| Q2 2021 | 7.81% |
| Q1 2021 | -4.46% |
| Q4 2020 | 3.02% |
| Q3 2020 | -1.99% |
| Q2 2020 | 48.02% |
| Q1 2020 | -4.82% |
| Q4 2019 | -5.76% |
| Q3 2019 | -6.43% |
| Q2 2019 | 34.88% |
| Q1 2019 | 27.89% |
| Q4 2018 | -6.02% |
| Q3 2018 | -6.36% |
| Q2 2018 | -6.95% |
| Q1 2018 | -3.59% |
| Q4 2017 | 46.86% |
| Q3 2017 | -5.30% |
| Q2 2017 | 26.49% |
| Q1 2017 | -10.21% |
| Q4 2016 | -3.82% |
| Q3 2016 | -5.01% |
| Q2 2016 | 4.95% |
| Q1 2016 | -5.02% |